Pregnane X receptor

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024
Nerve, Central nervous system, Metabolism, PXR, Alzheimer's disease, Testosterone, PCN, Research, MSI, Diabetic cardiomyopathy, Inflammation, Pathology, Deficit spending, Pregnane X receptor, MALDI, Neurotoxicity, Dysbiosis, JPA, Hippocampus, CYP, Heart failure, DCM, Domestic airport, Phenytoin, Mass spectrometry, PHT, Triglyceride, TMAO, Transplant, Glucocorticoid, Lipid metabolism, Patient, Journal, Glucose, Heart, Mouse, Glycated hemoglobin, Brain

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Nuclear Receptors and Drug-Drug Interactions: How to Better Understand Potential Toxicity, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, April 12, 2022
Metabolism, Absorption, Pharmacokinetics, ADME, Pharmacology, CAR, CSO, Aryl hydrocarbon receptor, FXR, Industry, Pennsylvania State University, DDI, PXR, Nuclear, Enzyme, Toxicity, Food, NFE2L2, Pregnane X receptor, Pharmaceutical industry

TORONTO, April 12, 2022  /PRNewswire-PRWeb/ -- Drug-drug interactions (DDI) resulting in adverse outcomes cause approximately 3% of all hospitalizations annually in the United States. This costs the health care system over a billion dollars. Fortunately, many aspects of DDI are predictable based on the increasing understanding of the mechanisms of altered absorption, distribution, metabolism and excretion (ADME).

Key Points: 
  • Attendees will also learn how these cell-based screening assays can be used to address species differences in the drug response.
  • TORONTO, April 12, 2022 /PRNewswire-PRWeb/ -- Drug-drug interactions (DDI) resulting in adverse outcomes cause approximately 3% of all hospitalizations annually in the United States.
  • Register for this webinar to learn about various drug screening assays that are available for identifying potential DDI in vitro.
  • For more information, or to register for this event, visit Nuclear Receptors and Drug-Drug Interactions: How to Better Understand Potential Toxicity.